IR2Dx is a privately held company at commercialization. Substantial foundations are now in place, with US and European patents issued. Data from clinical studies of more than 14,000 patients have been captured.

To date, the company has been funded by its founders, friends and families, physicians, colleagues, corporate partners and the management team. It was formed with a business strategy focused on capital and operating leverage.